9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma

Condition Mesothelioma|Solitary Fibrous Tumor of the Pleura Estimated Enrollment: 200 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective Study ID Numbers: 15-007645 Study First Received: November 20, 2015 Last Updated: December 19, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Survival status upon review of patients every 6 months|Progression free survival as evidenced by CT scan review Sponsors and Collaborators: Mayo Clinic Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02613312...

Continue reading

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Condition Mesothelioma Estimated Enrollment: 386 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment Study ID Numbers: POLARIS2015-003 Study First Received: March 5, 2016 Last Updated: January 25, 2017 Estimated Primary Completion Date: April 2018 Primary Outcome Measures: Response Rate|Progression Free Survival Sponsors and Collaborators: Polaris Group Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02709512...

Continue reading

A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

Condition Malignant Pleural Mesothelioma (MPM) Estimated Enrollment: 16 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: IRB14-1519 Study First Received: January 20, 2016 Last Updated: October 13, 2016 Estimated Primary Completion Date: February 2018 Primary Outcome Measures: Proportion of patients who show in vitro cytotoxic T lymphocyte induction to at least 2 of the 5 antigens determined by Enzyme-Linked ImmunoSpot (ELISPOT) assay|Toxicity per Common Terminology Criteria for Adverse Events (CTCAE) v4.03|Disease control rate defined as the proportion of patients who are assessed as having complete response (CR), partial response (PR), or...

Continue reading

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Condition Recurrent Malignant Mesothelioma|Stage IA Malignant Mesothelioma|Stage IB Malignant Mesothelioma|Stage II Malignant Mesothelioma|Stage III Malignant Mesothelioma|Stage IV Malignant Mesothelioma Estimated Enrollment: 36 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MC1023|NCI-2011-03574 Study First Received: December 16, 2011 Last Updated: August 25, 2016 Estimated Primary Completion Date: January 2019 Primary Outcome Measures: Adverse event (AE) profile|Describe the safety of the intrapleural administration of MV-NIS in patients with malignant pleural mesothelioma for all cycles out to 90 days. Sponsors and Collaborators: Mayo Clinic|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01503177...

Continue reading

Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 6 Age Group: 18 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: FAPME-1 Study First Received: October 31, 2012 Last Updated: May 10, 2016 Estimated Primary Completion Date: December 2016 Primary Outcome Measures: Safety Sponsors and Collaborators: University of Zurich Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01722149...

Continue reading

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

Condition Pleural Epithelioid Mesothelioma|Pleural Malignant Mesothelioma Estimated Enrollment: 10 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 15-000487|NCI-2015-01736|JCCCID552|P30CA016042 Study First Received: November 2, 2015 Last Updated: August 8, 2016 Estimated Primary Completion Date: January 2018 Primary Outcome Measures: Ability to accrue sufficient patients to draw conclusions about endpoints in a timely and expedient manner|Incidence of acute and subacute toxicity defined as grade 4 or 5 adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of chronic toxicity as assessed by the...

Continue reading

Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 54 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: INFLuenCe - Meso Study First Received: July 17, 2012 Last Updated: May 10, 2016 Estimated Primary Completion Date: August 2020 Primary Outcome Measures: number of participants with adverse events|local cisplatin concentration in the superficial chest wall tissue by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection|safety blood parameters (hematology and clinical chemistry)|overall survival|FFR freedom from recurrence = time to tumor progression by CT or PET-CT/MRI|change from baseline in SF-36 quality of life questionnaire|change from baseline...

Continue reading

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Condition Recurrent Pleural Malignant Mesothelioma|Stage IV Pleural Mesothelioma Estimated Enrollment: 55 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2015-010|NCI-2015-01412|1506014121|P30CA022453 Study First Received: October 2, 2015 Last Updated: March 28, 2017 Estimated Primary Completion Date: January 1, 2018 Primary Outcome Measures: Progression-free survival (PFS)|Incidence of grade 3-4 toxicity rate|Overall survival|Response rate (complete and partial response) Sponsors and Collaborators: Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02568449...

Continue reading

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Condition Mesothelioma|BAP1 Loss of Function Estimated Enrollment: 67 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: EZH-203 Study First Received: July 27, 2016 Last Updated: March 23, 2017 Estimated Primary Completion Date: September 2018 Primary Outcome Measures: Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Cmax|Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): Tmax|Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-t)|Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): AUC(0-∞)|Part 1: Pharmacokinetics profile of tazemetostat and its metabolite (plasma): t1/2|Part 1: Incidence of...

Continue reading

Autologous Dendritic Cell Vaccination in Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 20 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: CCRG13-002 Study First Received: December 7, 2015 Last Updated: January 24, 2017 Estimated Primary Completion Date: October 2020 Primary Outcome Measures: Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity Sponsors and Collaborators: University Hospital, Antwerp Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02649829...

Continue reading